vs
Side-by-side financial comparison of Baxter International (BAX) and SIRIUS XM HOLDINGS INC. (SIRI). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $2.2B, roughly 1.4× SIRIUS XM HOLDINGS INC.). SIRIUS XM HOLDINGS INC. runs the higher net margin — 4.5% vs -37.9%, a 42.4% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 0.2%). Over the past eight quarters, SIRIUS XM HOLDINGS INC.'s revenue compounded faster (0.7% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
XM Satellite Radio Holdings Inc. (XM) was one of the three satellite radio (SDARS) and online radio services in the United States and Canada, operated by Sirius XM Holdings. It provided pay-for-service radio, analogous to subscription cable television. Its service included 73 different music channels, 39 news, sports, talk and entertainment channels, 21 regional traffic and weather channels, and 23 play-by-play sports channels. XM channels were identified by Arbitron with the label "XM".
BAX vs SIRI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $2.2B |
| Net Profit | $-1.1B | $99.0M |
| Gross Margin | 19.4% | 53.1% |
| Operating Margin | -24.5% | 10.3% |
| Net Margin | -37.9% | 4.5% |
| Revenue YoY | 458.0% | 0.2% |
| Net Profit YoY | -120.3% | -55.4% |
| EPS (diluted) | $-2.21 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $2.2B | ||
| Q3 25 | $2.8B | $2.2B | ||
| Q2 25 | $2.8B | $2.1B | ||
| Q1 25 | $2.6B | $2.1B | ||
| Q4 24 | $533.0M | $2.2B | ||
| Q3 24 | $2.7B | $2.2B | ||
| Q2 24 | $3.8B | $2.2B | ||
| Q1 24 | $3.6B | $2.2B |
| Q4 25 | $-1.1B | $99.0M | ||
| Q3 25 | $-46.0M | $297.0M | ||
| Q2 25 | $91.0M | $205.0M | ||
| Q1 25 | $126.0M | $204.0M | ||
| Q4 24 | $-512.0M | $222.0M | ||
| Q3 24 | $140.0M | $-2.5B | ||
| Q2 24 | $-314.0M | $304.0M | ||
| Q1 24 | $37.0M | $265.0M |
| Q4 25 | 19.4% | 53.1% | ||
| Q3 25 | 33.5% | 52.2% | ||
| Q2 25 | 35.3% | 52.4% | ||
| Q1 25 | 32.8% | 52.0% | ||
| Q4 24 | 25.0% | 52.9% | ||
| Q3 24 | 38.3% | 53.2% | ||
| Q2 24 | 37.5% | 53.5% | ||
| Q1 24 | 38.6% | 52.5% |
| Q4 25 | -24.5% | 10.3% | ||
| Q3 25 | 6.1% | 22.8% | ||
| Q2 25 | 6.8% | 17.1% | ||
| Q1 25 | 2.2% | 18.7% | ||
| Q4 24 | -25.5% | 20.2% | ||
| Q3 24 | 5.7% | -133.6% | ||
| Q2 24 | -5.0% | 23.2% | ||
| Q1 24 | 5.2% | 20.2% |
| Q4 25 | -37.9% | 4.5% | ||
| Q3 25 | -1.6% | 13.8% | ||
| Q2 25 | 3.2% | 9.6% | ||
| Q1 25 | 4.8% | 9.9% | ||
| Q4 24 | -96.1% | 10.1% | ||
| Q3 24 | 5.2% | -113.1% | ||
| Q2 24 | -8.2% | 14.0% | ||
| Q1 24 | 1.0% | 12.3% |
| Q4 25 | $-2.21 | $0.23 | ||
| Q3 25 | $-0.09 | $0.84 | ||
| Q2 25 | $0.18 | $0.57 | ||
| Q1 25 | $0.25 | $0.59 | ||
| Q4 24 | $-0.99 | $2.45 | ||
| Q3 24 | $0.27 | $-8.74 | ||
| Q2 24 | $-0.62 | $0.08 | ||
| Q1 24 | $0.07 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | $94.0M |
| Total DebtLower is stronger | $9.5B | $8.6B |
| Stockholders' EquityBook value | $6.1B | $11.6B |
| Total Assets | $20.1B | $27.2B |
| Debt / EquityLower = less leverage | 1.55× | 0.75× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | $94.0M | ||
| Q3 25 | $1.7B | $79.0M | ||
| Q2 25 | $1.7B | $92.0M | ||
| Q1 25 | $2.3B | $127.0M | ||
| Q4 24 | $1.8B | $162.0M | ||
| Q3 24 | $1.4B | $127.0M | ||
| Q2 24 | $2.1B | $100.0M | ||
| Q1 24 | $3.0B | $71.0M |
| Q4 25 | $9.5B | $8.6B | ||
| Q3 25 | — | $9.0B | ||
| Q2 25 | — | $10.1B | ||
| Q1 25 | — | $10.4B | ||
| Q4 24 | $10.4B | $10.3B | ||
| Q3 24 | $10.4B | $10.1B | ||
| Q2 24 | $10.4B | $9.0B | ||
| Q1 24 | $11.1B | $8.7B |
| Q4 25 | $6.1B | $11.6B | ||
| Q3 25 | $7.2B | $11.6B | ||
| Q2 25 | $7.3B | $11.3B | ||
| Q1 25 | $7.1B | $11.2B | ||
| Q4 24 | $7.0B | $11.1B | ||
| Q3 24 | $7.9B | $10.9B | ||
| Q2 24 | $7.6B | $-2.1B | ||
| Q1 24 | $8.2B | $-2.4B |
| Q4 25 | $20.1B | $27.2B | ||
| Q3 25 | $21.1B | $27.4B | ||
| Q2 25 | $21.0B | $27.3B | ||
| Q1 25 | $21.3B | $27.4B | ||
| Q4 24 | $25.8B | $27.5B | ||
| Q3 24 | $26.7B | $27.5B | ||
| Q2 24 | $26.3B | $11.2B | ||
| Q1 24 | $27.8B | $11.2B |
| Q4 25 | 1.55× | 0.75× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.89× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | 1.49× | 0.93× | ||
| Q3 24 | 1.33× | 0.93× | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 1.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $680.0M |
| Free Cash FlowOCF − Capex | — | $536.0M |
| FCF MarginFCF / Revenue | — | 24.4% |
| Capex IntensityCapex / Revenue | — | 6.6% |
| Cash ConversionOCF / Net Profit | — | 6.87× |
| TTM Free Cash FlowTrailing 4 quarters | — | $1.2B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $680.0M | ||
| Q3 25 | $237.0M | $430.0M | ||
| Q2 25 | $217.0M | $546.0M | ||
| Q1 25 | $-193.0M | $242.0M | ||
| Q4 24 | $488.0M | $679.0M | ||
| Q3 24 | $253.0M | $240.0M | ||
| Q2 24 | $115.0M | $514.0M | ||
| Q1 24 | $163.0M | $308.0M |
| Q4 25 | — | $536.0M | ||
| Q3 25 | — | $255.0M | ||
| Q2 25 | — | $401.0M | ||
| Q1 25 | — | $53.0M | ||
| Q4 24 | — | $514.0M | ||
| Q3 24 | — | $24.0M | ||
| Q2 24 | — | $341.0M | ||
| Q1 24 | — | $134.0M |
| Q4 25 | — | 24.4% | ||
| Q3 25 | — | 11.8% | ||
| Q2 25 | — | 18.8% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 1.1% | ||
| Q2 24 | — | 15.7% | ||
| Q1 24 | — | 6.2% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | — | 6.8% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 7.5% | ||
| Q3 24 | — | 9.9% | ||
| Q2 24 | — | 7.9% | ||
| Q1 24 | — | 8.0% |
| Q4 25 | — | 6.87× | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | 2.38× | 2.66× | ||
| Q1 25 | -1.53× | 1.19× | ||
| Q4 24 | — | 3.06× | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | — | 1.69× | ||
| Q1 24 | 4.41× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
SIRI
| Subscription And Circulation | $1.6B | 74% |
| Advertising | $491.0M | 22% |
| Cost Of Sales Equipment Products And Services | $48.0M | 2% |
| Other Revenue | $28.0M | 1% |
